• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Vital Therapies inks plan for new phase 3 Elad trial

Vital Therapies inks plan for new phase 3 Elad trial

September 29, 2015 By Fink Densford

Vital TherapiesVital Therapies (NSDQ:VTL) outlined plans for a possible new phase 3 clinical trial to test its Elad treatment for liver failure in patients with alcohol-induced liver decompensation, according to an SEC filing posted yesterday.

The company is developing a cell-based therapy targeting the treatment of acute liver failure, using a cartridge system designed to produce cells that mimic those of a patient’s liver.

San Diego-based Vital Therapies halted a Phase III clinical trial of the Elad cell-based treatment for liver failure after it failed to meet its primary and secondary endpoints and shut down 2 other studies.

The plans for the new trial are based on “trends identified in pre-specified and post-hoc subset analyses of the subjects in the company’s recently completed VTI-208 phase 3 clinical trial,” according to the SEC filing.

Earlier this month, the company said it plans to lay off 32 employees, or about 30% of its workforce, and slash expenses as it looks to reboot its clinical program after the failure its Elad device in a trial last month.

The 203-patient VTI-208 trial, examining the efficacy of the cell-based therapy in treating subjects with alcohol-induced liver decomposition, found no difference between the control group and those treated with Elad in the primary endpoint of overall survival of at least 91 days. Secondary survival endpoints, at 28 and 91 days, and serious adverse events were also equivalent.

Vital Therapies said the layoffs, slated to be complete by the end of the year, are expected to cost $1.2 million during the 3rd quarter, including $900,000 in severance benefits.

Filed Under: Clinical Trials, Regenerative Medicine Tagged With: Vital Therapies

More recent news

  • Cognixion, Blackrock Neurotech ink distro deal for BCI tech
  • AdvaMed calls for medtech tariff exemptions at Senate hearing
  • GE HealthCare, Raydiant Oximetry partner on fetal oxygen saturation tech
  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy